Skip to main content
Explore URMC

CAAA617C12301 / RTOG-3517 / RGUP21042 / Novartis / Qiu

Research Question:
not to be listed

Basic Study Information

The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with mHSPC. In this study, the SoC is defined as a combination of Androgen Receptor Directed Therapy + Androgen Deprivation Therapy. Approximately 1126 patients will be randomized in this study.

Location: University of Rochester Cancer Center

Lead Researcher (Principal Investigator)

Lead Researcher:  Haoming Qiu

Study Contact Information

Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email:

Additional Study Details

Return to Search